In the latest trading session, 0.42 million Viracta Therapeutics Inc (NASDAQ:VIRX) shares changed hands as the company’s beta touched 0.69. With the company’s most recent per share price at $0.16 changed hands at -$0.01 or -7.34% at last look, the market valuation stands at $6.25M. VIRX’s current price is a discount, trading about -718.75% off its 52-week high of $1.31. The share price had its 52-week low at $0.13, which suggests the last value was 18.75% up since then. When we look at Viracta Therapeutics Inc’s average trading volume, we note the 10-day average is 2.8 million shares, with the 3-month average coming to 2.83 million.
Analysts gave the Viracta Therapeutics Inc (VIRX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended VIRX as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Viracta Therapeutics Inc’s EPS for the current quarter is expected to be -0.19.
Viracta Therapeutics Inc (NASDAQ:VIRX) trade information
Instantly VIRX was in red as seen in intraday trades today. With action -25.39%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -2.16%, with the 5-day performance at -25.39% in the red. However, in the 30-day time frame, Viracta Therapeutics Inc (NASDAQ:VIRX) is -17.06% down. Looking at the short shares, we see there were 2.69 million shares sold at short interest cover period of 1.85 days.
The consensus price target for the stock as assigned by Wall Street analysts is 8, meaning bulls need an upside of 98.0% from its recent market value. According to analyst projections, VIRX’s forecast low is 8 with 8 as the target high. To hit the forecast high, the stock’s price needs a -4900.0% plunge from its current level, while the stock would need to soar -4900.0% for it to hit the projected low.
Viracta Therapeutics Inc (VIRX) estimates and forecasts
Data shows that the Viracta Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -71.69% over the past 6 months, a 39.39% in annual growth rate that is considerably higher than the industry average of 16.30%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 44.96%. The 2025 estimates are for Viracta Therapeutics Inc earnings to increase by 35.23%.
VIRX Dividends
Viracta Therapeutics Inc is expected to release its next quarterly earnings report in February.
Viracta Therapeutics Inc (NASDAQ:VIRX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.84% of Viracta Therapeutics Inc shares while 50.06% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 51.52%. There are 50.06% institutions holding the Viracta Therapeutics Inc stock share, with BVF INC/IL the top institutional holder. As of 2024-06-30, the company held 9.192% of the shares, roughly 3.61 million VIRX shares worth $1.97 million.
CITADEL ADVISORS LLC holds the second largest percentage of outstanding shares, with 3.8659% or 1.52 million shares worth $0.83 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 652.91 shares estimated at $0.1 million under it, the former controlled 1.64% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.71% of the shares, roughly 282.49 shares worth around $44096.0.
